Why the study?
Does treatment with ADP and GPIIb/IIIa receptor antagonists reduce platelet activation during PTCA in patients undergoing angioplasty?
Population
45 patients undergoing percutaneous transluminal coronary angioplasty (PTCA)
Comparison
Treatment with platelet inhibitors vs Before treatment (baseline) / PTCA alone
Design
Cohort
Authors
Loading...
Combined ADP/GPIIb/IIIa antagonists may reduce antiplatelet efficacy during PTCA; hypothesis-generating for membrane fluidity markers.
Does treatment with ADP and GPIIb/IIIa receptor antagonists reduce platelet activation during PTCA in patients undergoing angioplasty?
Analysis of membrane fluidity provides a sensitive marker for platelet activation state, and combined platelet inhibitor treatments may have reduced antiplatelet efficacy.
Christov et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: